Fig. 2
PVRIG expression is associated with exhausted phenotype of tumor-infiltrating NK cells. a Percentage of PVRIG+ NK cells in PBMCs (blood), splenocytes (spleen), liver MNCs (liver) and lung MNCs (lung) from normal B6 mice (n = 4). b Percentage of PVRIG+ NK cells in splenocytes (Spl) and tumor-infiltrating lymphocytes (TIL) from WT mice (n = 3) or tumor-bearing mice subcutaneously injected with either 2 × 105 MC38 (n = 8), 2 × 105 MCA205 (n = 9) or 1 × 106 LLC (n = 5) cells, analyzed when tumor size reaches 300 mm3. c Geometric MFI of CD96, TIGIT, Tim-3, PD-1 or NKG2A in tumor-infiltrating PVRIG− NK cells (PVRIG− NK) and PVRIG+ NK cells (PVRIG+ NK) from MC38-bearing mice (n = 8 for CD96, TIGIT, Tim-3 and NKG2A; n = 7 for PD-1). d Geometric MFI of CD96, TIGIT, Tim-3, PD-1 or NKG2A in tumor-infiltrating PVRIG− NK cells (PVRIG− NK) and PVRIG+ NK cells (PVRIG+ NK) from MCA205-bearing mice (n = 9). e Geometric MFI of CD96, TIGIT, Tim-3, PD-1 or NKG2A in tumor-infiltrating PVRIG− NK cells (PVRIG− NK) and PVRIG+ NK cells (PVRIG+ NK) from LLC-bearing mice (n = 5). Each symbol represents an individual mouse (a–e), lines connect values for the same mouse (c–e). Data were representative of at least two independent experiments. Error bars represent means ± s.e.m. Statistical significance was determined using paired two-tailed t test (c–e) or one-way ANOVA followed by Tukey’s multiple-comparisons test (b). ns, not significant (p > 0.05); *p < 0.05; **p < 0.01; ***p < 0.001 and ****p < 0.0001